One of two federal lawsuits pursued by West Virginia and other states alleging that a number of generic drug makers engaged in a scheme to fix prices and allot market share took a step forward last week.
The judge denied the defendants’ joint motion to dismiss plaintiffs’ claims that the drug makers engaged in an overarching conspiracy, and allowed the plaintiffs to move forward to establish those claims.
Curtis Johnson, spokesman for Attorney General Patrick Morrisey, commented, “We believe the order is a big win for the states and private plaintiffs. We believe it has the potential to be a significant factor in moving the cases forward.”
Both suits are in the US District Court for the Eastern District of Pennsylvania before Judge Cynthia Rufe. Both allege that the defendant drug firms colluded to fix and raise prices, and to divvy up market share in order to avoid competition and maintain agreeable, inflated price.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK’s CMA Investigates Education Software Company for Market Abuse
May 14, 2024 by
CPI
Schumer Urges FTC Caution on Chevron’s $53B Hess Deal Over Gas Price Fears
May 14, 2024 by
CPI
Amazon Urges US Judge to Block FTC Probe into Data Preservation
May 14, 2024 by
CPI
Colorado Makes History: First State to Enact Comprehensive AI Legislation
May 14, 2024 by
CPI
Class Action Settlement Reached in Cheerleading Monopoly
May 14, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI